Accelerating Early Phase Oncology Development

Early phase oncology trials are more demanding than ever. Sponsors are expected to find the best dose earlier, in line with FDA’s Project Optimus guidance, rather than defaulting to the highest dose patients can tolerate. At the same time, they must manage increasingly complex study designs, reach more diverse patient populations, and coordinate dose escalation (testing increasing doses) and expansion cohorts across global sites, often with significant upfront investment. For small and emerging biotechs, these pressures can slow the path from first-in-human dosing to proof of concept.

Worldwide Clinical Trials brings deep early phase experience to these challenges. Most of its active oncology portfolio is made up of Phase I/II and first-in-human studies, supported by an alliance of early phase sites in North America, Europe, and Australia. Its teams combine dose-optimization know-how and experience running biomarker-driven trials with a flexible, biotech-minded approach. Seasoned oncology specialists and strong team continuity mean the same people stay with a study from start-up through expansion. Discover how to approach dose optimization, manage cohorts efficiently, and reach proof-of-concept milestones with confidence.